Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
Fuji
McKesson
Mallinckrodt
Federal Trade Commission
AstraZeneca
Farmers Insurance
Teva
QuintilesIMS
Dow

Generated: October 24, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,723,341

« Back to Dashboard

Which drugs does patent 6,723,341 protect, and when does it expire?


Patent 6,723,341 protects MOXATAG and is included in one NDA.

This patent has twenty-six patent family members in five countries.

Summary for Patent: 6,723,341

Title: Antibiotic product, use and formulation thereof
Abstract:An antibiotic product is comprised of at least three dosages forms, each of which has a different release profile, with the C.sub.max for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a C.sub.max at different times.
Inventor(s): Rudnic; Edward M. (N. Potomac, MD), Isbister; James D. (Potomac, MD), Treacy, Jr.; Donald J. (Annapolis, MD), Wassink; Sandra E. (Frederick, MD)
Assignee: Advancis Pharmaceutical Corp. (Germantown, MD)
Application Number:10/325,780
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Vernalis R And D Ltd
MOXATAG
amoxicillin
TABLET, EXTENDED RELEASE;ORAL050813-001Jan 23, 2008RXYesYes► Subscribe► SubscribeYY METHOD OF TREATING TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES IN A ONCE-A-DAY AMOXICILLIN PRODUCT
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,723,341

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,889,187Once a day amoxicillin product comprising immediate and delayed release dosage forms► Subscribe
6,541,014 Antiviral product, use and formulation thereof► Subscribe
7,025,989Multiple-delayed released antibiotic product, use and formulation thereof► Subscribe
7,108,859Antineoplastic product, use and formulation thereof► Subscribe
7,282,221Antiviral product, use and formulation thereof► Subscribe
6,669,948 Antibiotic product, use and formulation thereof► Subscribe
8,303,988Antifungal once-a-day product, use and formulation thereof► Subscribe
7,105,174Multiple-delayed release anti-neoplastic product, use and formulation thereof► Subscribe
6,667,042 Fluroquinilone antibiotic product, use and formulation thereof► Subscribe
7,157,095Multiple-delayed release antifungal product, use and formulation thereof► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,723,341

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan2006500344► Subscribe
Japan2005538121► Subscribe
Japan2005523309► Subscribe
Japan2003523378► Subscribe
Japan5377465► Subscribe
Japan2012001528► Subscribe
European Patent Office1545465► Subscribe
European Patent Office1542656► Subscribe
European Patent Office1465591► Subscribe
European Patent Office1257255► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

McKesson
US Army
Farmers Insurance
Teva
Cerilliant
UBS
McKinsey
Harvard Business School
Deloitte
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot